The Aspen share price held up reasonably well on Tuesday after confirmation that the European Commission had launched a Europe-wide investigation into alleged price hiking of critical cancer drugs. Although significantly off its 12 month-high of R385 on Tuesday Aspen closed 1.24% firmer at R278.72. In a Sens announcement released on Monday, Aspen said it was not in a position to comment on the commission’s proceedings, but confirmed its commitment to fair and open competition in markets in the EU and around the world. "Aspen takes compliance with competition laws very seriously and will work constructively with the European Commission in its process." Aspen, criticised in April for not informing shareholders of price-hiking investigations in Spain and the UK and a fine in Italy, has told shareholders it will keep them advised of any material developments. "Shareholders should exercise care when reacting to information on this matter, which has not been released by Aspen Holdings," t...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.